E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess and compare the efficacy (as measured by HbA1c) of adding liraglutide versus exenatide in subjects with type 2 diabetes, inadequately controlled on metformin, sulphonylurea or a combination of both, after 26 weeks. |
|
E.2.2 | Secondary objectives of the trial |
•To assess and compare the effect on other parameters of glycaemic control: FPG, self-measured 7-point plasma glucose profiles and fraction of subjects reaching target HbA1c of < 7.0% or ≤ 6.5% at week 26 •To assess and compare the effect on body weight •To assess and compare the incidence of hypoglycaemic episodes •To assess the safety and tolerability •To assess the formation of liraglutide and exenatide antibodies
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Informed consent obtained before any trial-related activities (trial-related activities are any procedure that would not have been performed during normal management of the subject) 2.Subjects diagnosed with type 2 diabetes and treated with either metformin, sulphonylurea or a combination of both, in a stable treatment regimen for at least 3 months prior to screening on maximally tolerated doses of these therapies, at the discretion of the Investigator (short-term change of metformin or sulphonylurea dose in connection with intercurrent illness within 3 months prior to screening is allowed, at the discretion of the Investigator) 3.HbA1c 7.0-11.0% (both inclusive) 4.Age 18-80 years, both inclusive (or as allowed according to local labelling for metformin, exenatide and sulphonylurea treatment) 5.Body Mass Index (BMI) ≤ 45.0 kg/m2
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria: 1.Previous treatment with insulin (except for short-term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator) 2.Any previous exposure to liraglutide or exenatide 3.Treatment with any hypoglycaemic agent(s) other than metformin or sulphonylurea in a period of 3 months prior to screening 4.Impaired liver function, defined as alanine aminotransferase (ALAT) ≥ 2.5 times upper normal limit (one retest analysed at the central laboratory within a week from receiving laboratory results is permitted with the result of the last sample being the conclusive) 5.Impaired renal function defined as serum-creatinine ≥ 135 µmol/L (≥ 1.5 mg/dL) for males and ≥ 115 µmol/L (≥ 1.3 mg/dL) for females, or as allowed according to local guidelines for metformin or sulphonylurea use (one retest analysed at the central laboratory within a week from receiving laboratory results is permitted with the result of the last sample being the conclusive) 6.Unstable angina, acute coronary event, other significant cardiac event (including history of arrhythmias or conduction delays on ECG), or cerebral stroke within the past 6 months 7.History of heart failure (NYHA class IV) 8.Known retinopathy or maculopathy requiring acute treatment as judged by the Investigator 9.Uncontrolled treated or untreated hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg) 10.Cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the Investigator’s opinion could interfere with the results of the trial 11.Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator 12.Known or suspected hypersensitivity to any components of the trial products 13.Use of any drug (except for metformin or sulphonylurea), which in the Investigator’s opinion could interfere with the glucose level (e.g. systemic corticosteroids) 14.Receipt of any other anti-diabetic investigational drug within 3 months prior to screening for this trial, or receipt of any investigational drugs not affecting diabetes within 1 month prior to screening for this trial 15.Any contraindications to the relevant background treatment or to exenatide according to the local labelling 16.Surgery scheduled for the trial duration period (excluding minor surgical procedures performed in local anaesthesia, as judged by the Investigator) 17.Previous participation in the randomised phase of this trial. Re-screening is allowed once within the recruitment period 18.Known or suspected abuse of alcohol or narcotics 19.Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice [for Germany adequate contraceptive measures are: implants, injectables, combined oral contraceptives, hormonal IUD, sexual abstinence or vasectomised partner]). 20.Inability to provide informed consent 21.Subjects with medical history of MEN2 or FMTC if total thyroidectomy has not been performed or cannot be ensured (i.e. posterior capsule of the thyroid gland not removed).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 14 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 61 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |